Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy
- Conditions
- Refractory IgA nephropathy
- Registration Number
- JPRN-C000000341
- Lead Sponsor
- Japanese Study Group of Multiple drug therapy for IgA
- Brief Summary
Forty five patients, 20 for Group A (corticosteroid, ARB/ACEI, anti-platelet agents) and 25 for Group B (same medications of Group A plus MZB), were analyzed. The baseline characteristics of patients between two groups did not significantly differ.The rate of clinical remission at 12M was significantly higher in group B(40%) than in Group A(7%)(P=0.049), but the difference was no-longer significant at 24M. Multiple-drug combind therapy using MZB may be a useful option for adult patients with intermediate-severrity IgAN.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
patients who's Ccr. Are Under 50ml/min or s-Cr. are over 2.0 mg/dl patients who have severe liver dysfunction pregnant or nursing women patients with a hypersensitivity to each thrapy drugs Judged inapproopriate for the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method